What happened
L&C BIO filed provisional (unaudited) separate results for Q2 2026: revenue of US$22.4M (+91.7% year on year), operating profit of US$6.26M (+624.8% year on year) and a net loss of US$19.4M.
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$22.4M |
|---|---|
| Revenue vs a year earlier | +91.7% |
| Operating profit | US$6.26M |
| Net income | −US$19.4M |
| Period | Q2 2026 (separate) |
| Filed | 2026-08-11, Operating results (preliminary) (fair disclosure) |
| Source | DART rcept 20260811900222 → open original filing |
Source: DART. Information only, not investment advice.